Immunoassay sample testing with extreme low sample consumption
Any Imperacer® assay can be adapted towards minimal sample consumption to support microsampling, microdosing and dried blood spot (DBS) trials.
Safe your sample, still maintaining sensitivity beyond the scope of conventional ELISA-type techniques.
Chimera Biotec Awarded Grant to Support Ultra Sensitive Efficacy Testing of an Oral and Nasal Vaccine Delivery Platformwith low volume mucosal tissue samples
Chimera Biotec GmbH, as specialist in ultra sensitive immunoassay development has received a significant project grant as part of a consortium looking to establish cold-chain independent virosome-based vaccine candidates.
Utilizing the proprietary Immuno-PCR based Imperacer® technology, Chimera aims to analyze vaccine specific immune-response in low volume preclinical sample material after oral and nasal administration of a nano-pharmaceutical vaccine.
A total project fund of €5.3 million has been awarded as part of Horizon 2020, the European Union research and innovation framework program, with additional funding of up to €3.1 million from the Swiss State Secretariat Education, Research and Innovation (SERI) for the Swiss based consortium partners, resulting in a total project grant of €8.4 million.
The EU Horizon 2020 project is named MACIVIVA, which stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines”. The total duration of the project is 3.5 years and joins experts in the field of vaccine virosomes, drug formulation and drug delivery. With Chimera Biotec, a leading expert in the field of ultra sensitive target quantification is part of the consortium.
Chimera Biotec will perform studies at its Dortmund-based laboratory, where it will use it´s expertise to enable vaccine efficacy analysis in different biofluids of the tested rat individuals. With the extremely high sensitivity of the Imperacer technology, a vaccine specific immune-response may not only be detectable in blood samples but also on mucosal samples collected from mucosal tissues, the port of entry of most pathogens.
The total project grant is distributed amongst all consortium partners: Chimera Biotec GmbH (Germany); Mymetics SA (Switzerland), Mymetics BV (Netherlands); Catalent (UK); Upperton Inc (UK) and Bachem AG (Switzerland).
“Chimera Biotec is looking forward to implement it´s know how on ultra sensitive target quantification in extremely low sample volumes into this global project and help to establish a new non-invasive cold-chain independent vaccine candidate” commented Beena Punnamoottil Sen. Project Manager at Chimera Biotec GmbH. “The success of this project will have a major impact on vaccinations strategies for new fields of vaccination and on global health care especially in countries with limited cold-chain availability.”
The MACIVIVA consortium recognizes the importance of this work and the impact it may have on global vaccine development.
The MACIVIVA project will receive funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 646122.